DiaMedica Therapeutics Inc.DMAC
| Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net loss | -6 | -11 | -12 | -14 | -14 | -19 | -24 |
|---|
| Share-based compensation | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
|---|
| Amortization of discounts on marketable securities | - | - | - | -0 | 0 | 1 | 1 |
|---|
| Non-cash lease expense | - | 0 | 0 | 0 | 0 | 0 | 0 |
|---|
| Depreciation | 15,000 | 21,000 | 21,000 | 0 | 25,000 | 30,000 | 39,000 |
|---|
| Amounts receivable | 1 | 0 | -0 | -0 | -0 | 0 | -0 |
|---|
| Prepaid expenses and other assets | 0 | -0 | 0 | 0 | 0 | 0 | -0 |
|---|
| Deposits | - | -0 | -0 | 0 | - | - | 1 |
|---|
| Accounts payable | - | -0 | 1 | -1 | 0 | 0 | 0 |
|---|
| Accrued liabilities | - | 0 | -0 | 0 | 0 | 0 | 2 |
|---|
| Net cash used in operating activities | -6 | -9 | -9 | -12 | -11 | -19 | -22 |
|---|
| Purchase of marketable securities | - | 13 | 40 | 70 | 46 | 69 | 50 |
|---|
| Maturities of marketable securities | - | 9 | 24 | 49 | 57 | 51 | 59 |
|---|
| Purchase of property and equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|---|
| Net cash provided by (used in) investing activities | -0 | -4 | -16 | -21 | 12 | -18 | 9 |
|---|
| Proceeds from issuance of common shares, net of offering costs | 15 | - | 29 | 30 | - | 37 | 12 |
|---|
| Proceeds from the exercise of stock options | 43,000 | 75,000 | 45,161 | 0 | - | - | 256,000 |
|---|
| Principal payments on finance lease obligations | - | 0 | 0 | 0 | 0 | 0 | 0 |
|---|
| Net cash provided by financing activities | 21 | 0 | 29 | 30 | -0 | 37 | 12 |
|---|
| Net decrease in cash and cash equivalents | - | - | 4 | -3 | 0 | -0 | -2 |
|---|
| Assets acquired under financing lease | - | - | - | - | - | - | 0 |
|---|
| Cash paid for income taxes | - | 0 | 0 | 0 | 0 | 0 | 0 |
|---|